Nicholas Navin, PhD

Nicholas Navin, PhD
Associate Professor
Department of Genetics
Department of Bioinformatics
University of Texas MD Anderson Cancer Center

Date:Tuesday May 30, 2017
Time:3:00 PM - 4:00 PM EDT
Location:Abramson Research Center (ARC)123C.

Single-cell sequencing technology has proven to be a powerful tool for understanding cancer evolution, the genomic diversity in tumors, and the mutations that fuel cancer progression. An associate professor of genetics and bioinformatics at MD Anderson Cancer Center, Nicholas Navin is currently applying this knowledge to help guide early detection, diagnosis, and targeted therapy for cancer patients. For his pioneering work, Navin won the 2015 AAAS Martin and Rose Wachtel Cancer Research Award, recognizing leading early-career scientists in the field of cancer research.

The Navin Lab has pioneered the development of single cell sequencing technologies and apply these tools to study complex biological processes that occur in human cancers including tumor initation, clonal evolution, invasion, metastasis and chemoresistance. These processes have previously been difficult to study with genomic technologies using bulk tissues. Dr. Navin's team is actively developing novel computational and statistical methods for analyzing large-scale single cell DNA and RNA sequencing datasets with a primary focus is on breast cancer patients.

About Dr. Navin
Dr. Navin is an associate professor at the MD Anderson Cancer Center where he holds a joint appointment in the Department of Genetics and Department of Bioinformatics and Computational Biology. He completed his postdoctoral studies at the Cold Spring Harbor Laboratory and graduate training at Stony Brook University in New York. Prior to his academic training, he worked as a computational biologist for several biotechnology companies. Dr. Navin has been the recipient of a number of prestigious scholarships and fellowships. His research has been highlighted in many news articles including Nature, Science, Nature Medicine, Scientific American, Nature Reviews Cancer, Nature Methods and the MIT Technology Review.